A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
Epistemonikos ID: c0d7f5c4f15ac764fa70d9823f1069447b4e5886
First added on: Mar 23, 2022